Last reviewed · How we verify

Pregabalin and dexmedetomidine

Wonkwang University Hospital · FDA-approved active Small molecule

Pregabalin and dexmedetomidine together enhance pain relief and sedation by increasing inhibitory neurotransmission and activating alpha-2 adrenergic receptors.

Pregabalin and dexmedetomidine together enhance pain relief and sedation by increasing inhibitory neurotransmission and activating alpha-2 adrenergic receptors. Used for Perioperative analgesia and sedation, Postoperative pain management.

At a glance

Generic namePregabalin and dexmedetomidine
Also known asstudy drugs
SponsorWonkwang University Hospital
Drug classCombination analgesic/sedative (gabapentinoid + alpha-2 agonist)
TargetAlpha-2-delta calcium channel subunit (pregabalin); alpha-2 adrenergic receptor (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia, Pain Management, Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Pregabalin is a gabapentinoid that binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release and providing analgesic and anxiolytic effects. Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis through central nervous system effects. The combination is used perioperatively to enhance anesthesia and analgesia while reducing opioid requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: